HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koller, W. C. Search for Related Content PubMed PubMed Citation Articles by Koller, W. C.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Treatment of early Parkinson’s disease

From the Department of Neurology, University of Miami School of Medicine, Miami, FL.

Address correspondence and reprint requests to Dr. William C. Koller, National Parkinson Foundation, 1501 NW 9th Avenue, Miami, FL 33136; e-mail: wkoller{at}med.miami.edu

The early treatment of Parkinson’s disease (PD) consists of nonpharmacologic treatment, consideration of neuroprotective therapy, and initial symptomatic treatment. Education for the patient and family, access to support groups, regular exercise, and good nutrition are essential to the overall management of PD. Disease-modifying therapies, such as agents that provide neurorescue or neuroprotection, will provide a major advance in the treatment of PD. Intervention at the genetic/environmental level or that affects the cascade of pathophysiologic events, protein aggregation, or apoptosis could result in neuroprotection. Many agents are now being investigated for neuroprotective potential. A major paradigm shift has recently occurred because of the recent basic and clinical data indicating that dopamine agonists, rather than levodopa, should be the initial symptomatic therapy in PD. However, levodopa may be started first in some patients because of patient age, cognitive status, or cost of drugs.

This article has been cited by other articles:

				B. D. Cakit, M. Saracoglu, H. Genc, H. R. Erdem, and L. Inan The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease Clinical Rehabilitation, August 1, 2007; 21(8): 698 - 705. [Abstract] [PDF]

				P. Jenner Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation Neurology, January 13, 2004; 62(90011): S47 - 55. [Abstract] [Full Text]